Revenue growth has reversed into a 4.7% contraction, while gross margins plummeted from 23.0% in 2024Q4 to 5.5% in 2025Q4, indicating a severe loss of pricing power.
| Sales/Revenue | 20.31M | 16.69M | 12.56M |
| Revenue Growth % | 21.72% | 32.91% | - |
| Cost of Goods Sold | 17.9M | 13.13M | 9.82M |
| COGS % of Revenue | 88.11% | 78.68% | 78.19% |
| Gross Profit | 2.42M | 3.56M | 2.74M |
| Gross Margin % | 11.89% | 21.32% | 21.81% |
| Gross Profit Growth % | -32.13% | 29.93% | - |
| Operating Expenses | 2.28M | 1.95M | 1.7M |
| OpEx % of Revenue | 11.24% | 11.69% | 13.5% |
| Selling, General & Admin | 2.22M | 1.89M | 1.76M |
| SG&A % of Revenue | 10.91% | 11.32% | 14% |
| Research & Development | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 67.26K | 60.95K | -62.95K |
| Operating Income | 132.04K | 1.61M | 1.04M |
| Operating Margin % | 0.65% | 9.64% | 8.31% |
| Operating Income Growth % | -91.79% | 54.08% | - |
| EBITDA | 1.21M | 2.53M | 1.76M |
| EBITDA Margin % | 5.93% | 15.18% | 14% |
| EBITDA Growth % | -52.43% | 44.1% | - |
| D&A (Non-Cash Add-back) | 1.07M | 925.58K | 714.59K |
| EBIT | 133.78K | 1.61M | 1.04M |
| Net Interest Income | -95.93K | -82.29K | -23.02K |
| Interest Income | 1.74K | 474 | 219 |
| Interest Expense | 97.67K | 82.77K | 23.24K |
| Other Income/Expense | -95.93K | -82.29K | -23.02K |
| Pretax Income | 36.11K | 1.53M | 1.02M |
| Pretax Margin % | 0.18% | 9.14% | 8.13% |
| Income Tax | 63.17K | 196.25K | 22.57K |
| Effective Tax Rate % | 174.92% | 12.86% | 2.21% |
| Net Income | -27.06K | 1.33M | 998.2K |
| Net Margin % | -0.13% | 7.97% | 7.95% |
| Net Income Growth % | -102.03% | 33.21% | - |
| Net Income (Continuing) | -27.06K | 1.33M | 998.2K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -0.00 | 0.18 | 0.09 |
| EPS Growth % | -101.67% | 98.46% | - |
| EPS (Basic) | -0.00 | 0.18 | 0.09 |
| Diluted Shares Outstanding | 10.21M | 7.37M | 11M |
| Basic Shares Outstanding | 9.02M | 7.37M | 11M |
| Dividend Payout Ratio | - | - | - |
Liquidity and Regulatory Volatility
As indicated by the most recent quarterly financial data, HKPD experienced a revenue contraction of 4.7% in 2025Q4, marking a significant reversal from the earlier growth phases observed since the company's inception in late 2023, which warrants close monitoring of its core wholesale volume.
The sudden shift from growth to contraction suggests that the company's initial market penetration strategy may be losing momentum or encountering increased competitive friction. Investors should consider whether this decline reflects a broader softening in cross-border pharmaceutical demand or specific operational challenges in maintaining its niche regulatory-compliant distribution channels.
According to the latest income statement filings, HKPD's gross margin plummeted to 5.5% in 2025Q4, down from 23.0% in 2024Q4, highlighting a severe erosion of pricing power and an inability to pass through rising procurement costs in its high-volume pharmaceutical distribution model.
This rapid margin compression implies that the company is struggling to maintain its value proposition as an intermediary, potentially due to aggressive discounting or rising inventory acquisition costs. The inability to sustain double-digit margins suggests that the current business model lacks the structural pricing power necessary to absorb fluctuations in the Hong Kong-Mainland China trade corridor.
Based on reported figures, HKPD's operating margin swung to a negative 9.7% in 2025Q4, demonstrating that the company's fixed cost base, particularly its warehousing and administrative overhead, is no longer being adequately covered by the declining gross profit generated from its wholesale operations.
The transition from a 13.4% operating margin in 2024Q4 to a significant loss in the most recent period indicates a lack of operational scalability. This suggests that the company's cost structure is currently too rigid to adapt to lower revenue levels, creating a high-risk environment where further volume declines could rapidly exacerbate net losses.
Financial statements reveal that HKPD's net income has deteriorated to a loss of $855.6K in 2025Q4, raising serious questions about the viability of its current principal-based accounting model and the company's ability to achieve long-term profitability without significant capital injections or a strategic pivot.
Short-sellers would likely focus on the company's inability to maintain positive net margins despite its specialized regulatory niche, suggesting that the 'toll-booth' advantage may be less durable than initially perceived. The combination of shrinking margins and negative cash flow indicates that the company may be approaching a critical inflection point where its current liquidity position becomes insufficient to support ongoing operations.
Quick answers to the most common questions about buying HKPD stock.
For fiscal year 2025, Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported total revenue of $20.3M. This represents a 61.8% increase compared to $12.6M in 2023.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported a net loss of $0.0M for the fiscal year ending 2025.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported an operating income of $0.1M, resulting in an operating profit margin of 0.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) generated $2.4M in gross profit for the year, representing a gross profit margin of 11.9%. This demonstrates the company's core pricing power and production efficiency.